Circulation:γδT细胞介导血管紧张素II诱导的高血压和血管损伤

2017-03-31 MedSci MedSci原创

抗原呈递细胞和适应性免疫T细胞已被报道参与高血压的发展。然而,涉及高血压病理生理学的T淋巴细胞亚群仍不清楚。近期加拿大学者发表研究文章于著名血管期刊Circulation,研究一小部分表达γδT细胞受体(TCR)而不是αβTCR的固有T细胞亚群可能在高血压免疫应答中起作用。本研究目的是确定血管紧张素(Ang)II是否引起γδT细胞的动态变化,γδT细胞缺失阻断Ang II诱导的高血压、血管损伤和T

抗原呈递细胞和适应性免疫T细胞已被报道参与高血压的发展。然而,涉及高血压病理生理学的T淋巴细胞亚群仍不清楚。

近期加拿大学者发表研究文章于著名血管期刊Circulation,研究一小部分表达γδT细胞受体(TCR)而不是αβTCR的固有T细胞亚群可能在高血压免疫应答中起作用。本研究目的是确定血管紧张素(Ang)II是否引起γδT细胞的动态变化,γδT细胞缺失阻断Ang II诱导的高血压、血管损伤和T细胞活化,γδT细胞是否与人类高血压相关。

给予雄性C57BL/6野生型(WT)小鼠和缺失γδT细胞的Tcrδ-/-小鼠,或注射了对照IgG或γδT细胞消耗性抗体的WT小鼠注射Ang II无、或3,7,14天处理。通过流式细胞术测定T细胞谱,通过加压造影术、遥测技术和肠系膜动脉内皮功能测定收缩压。TCRγ恒定基因表达水平和全血基因表达微阵列研究(包括血压正常和高血压受试者)的临床资料用于证实γδT细胞与收缩压之间的关联。

7天和14天Ang II处理增加WT小鼠脾脏中γδT细胞的数量和活性(P <0.05)。14天Ang II输注增加WT小鼠收缩压(P <0.01),降低肠系膜动脉内皮功能(P <0.01),而Tcrδ - / - 小鼠中并无两个现象(P <0.01)。与对照IgG处理的Ang II输注小鼠相比, TCRγδ抗体诱导的γδT细胞缺失阻断了Ang II诱导的收缩压升高和内皮功能障碍(P <0.05)。脾脏和血管周围脂肪组织中Ang II诱导的T细胞活化被小鼠Tcrδ - / - 阻断(P <0.01)。在人类,整合全血TCRγ恒定基因表达水平,年龄和性别做多元线性回归模型证实收缩压和γδT细胞之间的关联(R2 = 0.12,P <1×10-6)。

γδT细胞介导Ang II诱导的小鼠收缩压升高,血管损伤和T细胞活化。γδT细胞可能促进人类高血压的发展。

原始出处:Caillon A, Mian MO,et al. Gamma Delta T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injury.Circulation. 2017 Mar 22. pii: CIRCULATIONAHA.116.027058.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1705699, encodeId=dd1a1e0569913, content=<a href='/topic/show?id=8e408966501' target=_blank style='color:#2F92EE;'>#血管损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89665, encryptionId=8e408966501, topicName=血管损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84ba31025715, createdName=bbwuyu_013, createdTime=Sat Sep 09 23:00:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218229, encodeId=236e21822945, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Jul 03 22:10:57 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397155, encodeId=696d139e155b8, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506858, encodeId=029015068581d, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589294, encodeId=7402158929418, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1705699, encodeId=dd1a1e0569913, content=<a href='/topic/show?id=8e408966501' target=_blank style='color:#2F92EE;'>#血管损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89665, encryptionId=8e408966501, topicName=血管损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84ba31025715, createdName=bbwuyu_013, createdTime=Sat Sep 09 23:00:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218229, encodeId=236e21822945, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Jul 03 22:10:57 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397155, encodeId=696d139e155b8, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506858, encodeId=029015068581d, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589294, encodeId=7402158929418, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=)]
    2017-07-03 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1705699, encodeId=dd1a1e0569913, content=<a href='/topic/show?id=8e408966501' target=_blank style='color:#2F92EE;'>#血管损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89665, encryptionId=8e408966501, topicName=血管损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84ba31025715, createdName=bbwuyu_013, createdTime=Sat Sep 09 23:00:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218229, encodeId=236e21822945, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Jul 03 22:10:57 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397155, encodeId=696d139e155b8, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506858, encodeId=029015068581d, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589294, encodeId=7402158929418, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1705699, encodeId=dd1a1e0569913, content=<a href='/topic/show?id=8e408966501' target=_blank style='color:#2F92EE;'>#血管损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89665, encryptionId=8e408966501, topicName=血管损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84ba31025715, createdName=bbwuyu_013, createdTime=Sat Sep 09 23:00:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218229, encodeId=236e21822945, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Jul 03 22:10:57 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397155, encodeId=696d139e155b8, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506858, encodeId=029015068581d, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589294, encodeId=7402158929418, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1705699, encodeId=dd1a1e0569913, content=<a href='/topic/show?id=8e408966501' target=_blank style='color:#2F92EE;'>#血管损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89665, encryptionId=8e408966501, topicName=血管损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84ba31025715, createdName=bbwuyu_013, createdTime=Sat Sep 09 23:00:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218229, encodeId=236e21822945, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Jul 03 22:10:57 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397155, encodeId=696d139e155b8, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506858, encodeId=029015068581d, content=<a href='/topic/show?id=26cf89e4530' target=_blank style='color:#2F92EE;'>#血管紧张素II#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89745, encryptionId=26cf89e4530, topicName=血管紧张素II)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab559833295, createdName=bbwznl, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589294, encodeId=7402158929418, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Sat Apr 01 15:00:00 CST 2017, time=2017-04-01, status=1, ipAttribution=)]

相关资讯

CNS:近期癌症免疫疗法突破性研究成果一览

癌症免疫疗法是一种直接针对人类机体免疫系统,而并非直接对肿瘤进行作用的新型疗法,该疗法已经有30多年历史了,其是通过利用患者自身的抵抗力来杀灭肿瘤细胞达到抵御癌症的目的,是近年来肿瘤治疗的一个新方向,也是当前癌症研究领域中的热点之一。 如今,治疗癌症的免疫疗法是人们非常关注的一个热点领域,那么近年来癌症免疫疗法研究领域又有哪些突破性的研究成果呢? 本文中小编盘点了CNS近期癌症免疫疗

Nature Communication:调节T细胞的钙通道抑制肠炎和GVHD

这项研究阐述了CRAC钙通道各个蛋白的功能,并且发现通过调节免疫细胞中钙离子的量能过调节T细胞的免疫反应程度,为未来通过调节钙通道来调节T细胞的免疫提供了理论基础。

JCO:来那度胺治疗成人T细胞淋巴瘤恶化或复发前景喜人

T细胞淋巴瘤是罕见的非霍奇金淋巴瘤。2016年12月,发表在《J Clin Oncol》的一项由日本科学家进行的研究考察了来那度胺治疗成人T细胞淋巴瘤恶化或复发的安全性和有效性。

Nature:法国学者研究组揭示艾滋病病毒表面隐藏蛋白

2017年3月15日,国际学术权威刊物自然出版集团《Nature》杂志在线发表了法国蒙彼利埃大学Monsef Benkirane研究员的一篇研究论文,研究发现潜藏艾滋病病毒(HIV)的T细胞表面特定表达着一种名叫CD32a的蛋白

盘点:CRISPR基因编辑技术或有望治疗癌症和HIV等顽疾

CRISPR/Cas系统是大多数细菌与所有的古菌中的一种后天免疫系统,其全名为常间回文重复序列丛集/常间回文重复序列丛集关联蛋白系统,能够以消灭外来的质体或者噬菌体并在自身基因组中留下外来基因片段作为“记忆”。近年来以CRISPR/Cas9为基础的基因编辑技术在一系列基因治疗的应用领域都展现出极大的应用前景,比如艾滋病、血液病、肿瘤等多种人类顽疾;那么近期CRISPR-Cas9基因编辑

2017年3月份生物谷推荐的HIV亮点研究

2017年3月19日/生物谷BIOON/---人类免疫缺陷病毒(human immunodeficiency virus, HIV),即艾滋病(AIDS,获得性免疫缺陷综合征)病毒,是造成人类免疫系统缺陷的一种病毒。1983年,HIV在美国首次发现。它是一种感染人类免疫系统细胞的慢病毒(lentivirus),属逆转录病毒的一种。 HIV通过破坏人体的T淋巴细胞,进而阻断细胞免疫和体